Please login to the form below

Not currently logged in
Email:
Password:

PD-L1 inhibitor

This page shows the latest PD-L1 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Regeneron’s fianlimab/Libtayo combination shows positive results in advanced melanoma treatment

Regeneron’s fianlimab/Libtayo combination shows positive results in advanced melanoma treatment

L1 inhibitor (PD-1/PD-L1-naïve) and one of patients who had received prior PD-1 or PD-L1 inhibitor therapy (PD-1/PD-L1-experienced). ... The objective response rate (ORR) in the PD-1/PD-L1-experienced cohort was 13%.

Latest news

More from news
Approximately 8 fully matching, plus 171 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies. ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast.

  • Pharma deals during November 2014 Pharma deals during November 2014

    AZ has been busy this month and in the deal with J&J, AZ will match its closely-watched PD-L1 checkpoint inhibitor MEDI4736 with Imbruvica. ... This deal gives Pfizer co-development and co-marketing rights to MSB0010718C, Merck KGaA's anti-PD-L1

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Top-10 Reasons Why You Should be Adding Asynchronous Virtual Touchpoints Between Your Real-time Meetings
...
Flu
Influenza – the risk to vulnerable populations
Why we can't get complacent about flu vaccination...
dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...